Literature DB >> 15293601

Clinical prognostic indicators of high-grade pre-invasive bronchial lesions.

D Moro-Sibilot1, F Fievet, M Jeanmart, S Lantuejoul, F Arbib, M H Laverribre, E Brambilla, C Brambilla.   

Abstract

Lung cancer arises from multistep genetic damage of bronchial epithelium, driving multifocal progressive dysplastic lesions. However, the risk of progression of high-grade pre-invasive bronchial lesions to cancer is poorly assessed. The purpose of this study was to better define the parameters that predict the outcome of these lesions. The current authors prospectively studied 27 patients with 31 histologically proven severe dysplasia (SD) and carcinoma in situ (CIS), with repeated bronchoscopy and endobronchial treatment. The influence of respiratory-cancer history, histopathological classification, tobacco consumption, and number of biopsies on the progression rate into cancer was studied. The actuarial progression rate to cancer was 17% at 1 yr and 63% at 3 yrs. A total of 11 cases of CIS progressed to invasive cancer, 17 were stable or regressed during the study, two with SD regressed and one progressed to invasive cancer. Progression of CIS appeared more frequent in lesions diagnosed as "questionable CIS". Persistence of smoking did not influence high-grade lesion outcome. The existence of synchronous lung cancer did not seem to impact on progression. The number of biopsies did not influence the outcome. In conclusion, the current study suggests that the outcome of high-grade pre-invasive lesions is not modified by the number of biopsies performed on these lesions. Careful pathological examination of these lesions and pathological revision seem necessary, since questionable cases have the worse progression rate.

Entities:  

Mesh:

Year:  2004        PMID: 15293601     DOI: 10.1183/09031936.04.00065303

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  Association of progressive structural changes in the bronchial epithelium with subepithelial fibrous remodeling: a potential role for hypoxia.

Authors:  Vasiliy V Polosukhin; William E Lawson; Aaron P Milstone; Svetlana M Egunova; Andrey G Kulipanov; Sergey G Tchuvakin; Pierre P Massion; Timothy S Blackwell
Journal:  Virchows Arch       Date:  2007-08-03       Impact factor: 4.064

2.  Surveillance for the detection of early lung cancer in patients with bronchial dysplasia.

Authors:  Philip Jeremy George; Anindo K Banerjee; Catherine A Read; Caoihme O'Sullivan; Mary Falzon; Francesco Pezzella; Andrew G Nicholson; Penny Shaw; Geoff Laurent; Pamela H Rabbitts
Journal:  Thorax       Date:  2006-07-06       Impact factor: 9.139

Review 3.  Natural history of bronchial preinvasive lesions.

Authors:  Taichiro Ishizumi; Annette McWilliams; Calum MacAulay; Adi Gazdar; Stephen Lam
Journal:  Cancer Metastasis Rev       Date:  2010-03       Impact factor: 9.264

4.  Detection and minimally invasive treatment of early squamous lung cancer.

Authors:  Johannes M A Daniels; Thomas G Sutedja
Journal:  Ther Adv Med Oncol       Date:  2013-07       Impact factor: 8.168

Review 5.  The technique of endoscopic airway tumor treatment.

Authors:  Simone Scarlata; Lello Fuso; Gabriele Lucantoni; Francesco Varone; Daniele Magnini; Raffaele Antonelli Incalzi; Gianni Galluccio
Journal:  J Thorac Dis       Date:  2017-08       Impact factor: 2.895

6.  Persistence of Bronchial Dysplasia Is Associated with Development of Invasive Squamous Cell Carcinoma.

Authors:  Daniel T Merrick; Dexiang Gao; York E Miller; Robert L Keith; Anna E Baron; William Feser; Timothy C Kennedy; Patrick J Blatchford; Sarah Braudrick; Fred R Hirsch; Lynn Heasley; Paul A Bunn; Wilbur A Franklin
Journal:  Cancer Prev Res (Phila)       Date:  2015-11-05

Review 7.  The promises and challenges of early non-small cell lung cancer detection: patient perceptions, low-dose CT screening, bronchoscopy and biomarkers.

Authors:  Lukas Kalinke; Ricky Thakrar; Sam M Janes
Journal:  Mol Oncol       Date:  2020-12-14       Impact factor: 6.603

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.